Are you Dr. Malek?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 46 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
225 Quincy Ave
Brockton, MA 02302Phone+1 508-586-1410
Summary
- Dr. Karim Malek, MD is an oncologist in Brockton, Massachusetts. He is currently licensed to practice medicine in Massachusetts, Minnesota, and Montana. He is affiliated with Signature Healthcare Brockton Hospital and is an Assistant Clinical Professor at Tufts Medical Center.
Education & Training
Boston University Medical CenterResidency, Internal Medicine, 1999 - 2002- Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
University of Alexandria Faculty of MedicineClass of 1988
Certifications & Licensure
MA State Medical License 1999 - 2026
MN State Medical License 2024 - 2026
MT State Medical License 2024 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 87 citationsPhase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with pl...David M. O'Malley, Ursula A. Matulonis, Michael J. Birrer, Cesar M. Castro, Lucy Gilbert
Gynecologic Oncology. 2020-02-18 - 40 citationsEvaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab SoravtansineUrsula A. Matulonis, Michael J. Birrer, David M. O'Malley, Kathleen N. Moore, Jason A. Konner
Clinical Cancer Research. 2019-03-15 - 55 citationsSafety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in c...Kathleen N. Moore, David M. O'Malley, Ignace Vergote, Lainie P. Martin, Antonio González-Martín
Gynecologic Oncology. 2018-10-01
Press Mentions
FDA Grants Fast Track Designation to Aveta Biomics’ Drug APG-157 for Neoadjuvant Treatment of Head and Neck CancerAugust 22nd, 2024- Intellisee AI Risk Mitigation Platform Announces Product Launch: New Company Offers “Smarter Surveillance for a Safer World”September 14th, 2020
Professional Memberships
- Member
